Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen J M
Clin Pharmacol Ther. 1975 Jun;17(6):731-4. doi: 10.1002/cpt1975176731.
The influence of sulfamethizole on the metabolism of diphenylhydatoin (DPH) tolbutamide, and warefarian is examined. In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min. In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min. In 4 patients on long-term DPH treatment after 1 wk on sulfamethizole inhibits hepatic metabolism of DPH, tolbutamide, and warfarin.
研究了磺胺甲噻二唑对苯妥英钠(DPH)、甲苯磺丁脲和华法林代谢的影响。在8例患者中,DPH的平均半衰期(T/2)从11.8±3.6小时增加到19.6±5.2小时,平均代谢清除率(MCR)从43.7±16.8降至28.1±9.1毫升/分钟;在另外2例患者中,华法林的T/2从平均64.7小时增加到92.7小时,MCR从1.65毫升/分钟降至1.05毫升/分钟。在4例长期接受DPH治疗的患者中,服用磺胺甲噻二唑1周后,其抑制了DPH、甲苯磺丁脲和华法林的肝脏代谢。